This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Harnessing the power of single-cell and spatial genomics to understand how immune cells sense and respond to the tumor microenvironment is a major focus of Dr. Ye’s research. In his laboratory, he and his colleagues have initially developed XYZeq, a novel method for spatially-resolved single-cell genomics to map immune cells and their environment within the complex architecture of solid tumors. The first aim of this proposal is to improve the spatial resolution of XYZeq in order to deploy the technology to profile a broad range of tumors. The next aim is to use XYZeq to identify which T cell receptors (TCRs) are predominant in tumors and associated with an activated, tumor-killing state. This would identify TCRs that may lead to better candidates for engineering T cells which can more effectively attack solid tumors. Finally, XYZeq will be integrated with genetic screens to identify synthetic receptors and transcriptional circuits that allow engineered T cells to overcome the immunosuppressive tumor microenvironment.
University of California, San Francisco | All Cancers | 2022
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).